COX-2 inhibitors as adjunctive therapy in schizophrenia

Expert Opinion on Investigational Drugs

Volumn 13, Issue 8, 2004, Pages 1033-1044

  Müller, Norbert ^a   Strassnig, Martin ^a   Schwarz, Marcus J ^a   Ulmschneider, Markus ^a   Riedel, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cognition; COX 2; Cyclooxygenase; Depression; Immunology; Inflammation; Schizophrenia

Indexed keywords

ACETYLCHOLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CELECOXIB; CLOZAPINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIZOCILPINE; DRUG METABOLITE; GLUTAMIC ACID; KAINIC ACID; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN E2; RISPERIDONE; ROFECOXIB; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ACUTE DISEASE; ADD ON THERAPY; ALZHEIMER DISEASE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG RESEARCH; DRUG SELECTIVITY; ENCEPHALITIS; HUMAN; IMMUNOREGULATION; MEDICAL ETHICS; MENTAL DISEASE; MOLECULAR INTERACTION; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; THEORY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; CYCLOOXYGENASE INHIBITORS; HUMANS; SCHIZOPHRENIA;

EID: 4344614138     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.8.1033     Document Type: Review

References (119)

1. MENNINGER KA: Psychoses associated with influenza. J. Am. Med. Assoc. (1919) 72:235-241.
2. MENNINGER KA: Influenza and schizophrenia. An analysis of postinfluenza 'dementia praecox' as of 1918 and five years later. Am. J. Psychiatry (1926) 5:469-529.
3. MENNINGER KA. The schizophrenia syndrome as a product of acute infectious disease. Arch. Neurol. Psychiatry (1928) 20:464-481.
4. WISE TN, LA BUFFE FP, GRANGER ST: Meningo encephalitis presenting as an acute paranoid psychosis. Int. J. Psychiatry Med. (1977) 8:405-414
5. SCHLITT M, LAKEMAN FD, WHITLEY RJ: Psychosis and herpes simplex encephalitis. South Med. J. (1985) 78:1347-1350.
6. HOWARD JS 3rd: Herpes encephalitis, schizophrenia and the crossroad of psychiatry. Integr. Physiol. Behav. Sci. (1996) 31:219-223.
7. KRÜGER KW: Lupus erythematodes und Zentralnervensystem. Nervenarzt (1984) 55:165-172.
8. RAPS A, ABRAMOVICH Y, ASSAEL M: Relation between schizophrenic-like psychosis and Sjögren Syndrome (SS). Isr. J. Psychiatry Relat. Sci. (1986) 23:321-324.
9. MÜLLER N, GIZYCKI-NIENHAUS B, GÜNTHER W et al.: Depression as a possible cerebral manifestation of scleroderma: immunological findings in serum and CSF. Biol. Psychiatry 11992) 31:1151-1156.
10. KURTZ G, MÜLLER N: The antiphospholipid syndrome and psychosis. Am. J. Psychiatry (1994) 151:1841-1842.
11. KÖRSCHENHAUSEN D, HAMPEL H, ACKENHEIL M et al.: Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. (1996) 19:103-109.
12. WILDENAUER D, HOECHTLEN W: Liquorproteine bei psychiatrischen Erkrankungen. In: Pychoimmunologie. WP Kaschka, NH Aschauef (Eds), Thieme, Stuttgart, NY (1990):75-81.
13. O'BANION MK: Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. (1999) 13:45-82.
14. VANE JR, BOTTING RM: Mechanism of action of aspirin-like drugs. Semin. Arthritis Rheum. (1997) 6(Suppl. 1):2-10.
15. HILKENS CM, SNIJDERS A, SNIJDEWINT FG et al.: Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur. Respir. J. (1996) Suppl. 22:90s-94s.
16. YAMAGATA K, ANDREASSON KI, KAUFMANN WE et al.: Expression of a mitogen-inductible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 11:371-386.
17. KAM PC, SEE AU: Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia (2000) 55:442-449.
18. KAUFMANN WE, ANDREASON KI, ISAKSON PC et al: Cyclooxygenases and the central nervous system. Prostaglandins (1997) 54:601-624.
19. MATSUMURA K, WATANABE Y, IMAI-MATSUMURA K et al: Mapping of prostaglandin e2 binding sites in rat brain using quantitative autoradiography. Brain Res. (1992) 581:292-298.
20. FRANK E, SWARTZ HA, KUPFER DJ: Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol. Psychiatry (2000) 43:593-604.
21. KAUFMANN WE, WORLEY PF, PEGG J et al.: Cox-2, a synaptically induced enzyme, is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. USA (1996) 93:2317-2321.
22. BREDER CD, SAPER CB: Expression of inductible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res. (1996) 713:64-69.
23. ADAMS J, COLLACO-MORAES Y, DE BELLEROCHE J: Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J. Neurochem. (1996) 66:6-13.
24. PLANAS AM, SORIANO MA, JUSTICIA C et al.: Introduction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosi. Lett. (1999) 275:141-144.
25. PLANAS AM, SORIANO MA, RODRIGUEZ-FARR E et al.: Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci. Lett. (1995) 200:187-190.
26. TOCCO G, FREIRE MJ, SCHREIBER SS et al.: Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implication for Alzheimer's disease. Exp. Neurol. (1997) 144:339-349.
27. BREDER CD, DEWITT D, KRAIG RP: Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. (1995) 355:296-315.
28. WORLEY PF, CHRISTY BA, NAKABEPPU Y et al.: Constitutive expression of Zif268 in neocortex is regulated by synaptic activity. Proc. Natl. Acad Sci. USA (1991) 88:5106-5110.
29. FAGARASAN MO, AISEN PS: Il-1 and anti-inflammatory drugs modulate A-β cytotoxicity in PC12 cells. Brain Res. (1996) 723:231-234.
30. CAMPBELL IL, ABRAHAM CR, MASLIAH E et al. : Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA (1993) 90:10061-10065
31. LEONARD BE: The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiat. (2001) 25:767-780.
32. RAPOPORT SI, BOSETTI F: Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry. (2002) 59:592-596.
33. BOSETTI F, WEERASINGHE GR, ROSENBERGER TA et al. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cycloocygenase-1 and -2 in rat brain. J. Neurochemistry (2003) 85:690-696.
34. BOSETTI F, RINTALA J, SEEMANN R et al: Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin e2 concentration in rat brain. Mol. Psychiatry (2003) 7:845-850.
35. DAS I, KHAN NS: Increased arachidonic acid induced platelet chemoluminiscence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins, Leukot. Essent. Fatty Acids (1998) 58:165-168.
36. WILLARD LB, HAUSS-WEGRZYNIAK B, DANYSZ W et al.: The cytotoxicity of chronic neuroninflammation upon basal forebrain cholingergic neurons of rats can be attenuated by gluatamatergic atagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. (2000) 134:58-65.
37. ARAKI E, FORSTER C, DUBINSKY J et al.: Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures form lipopolysaccharide-induced neurotoxicity. Stroke (2001) 32:2370-2375.
38. HEWETT SJ, ULIASY TF, VIDWANS AS et al.: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. (2000) 293:417-425.
39. COLE DJ, PATEL PM, SCHELL RM et al.: Brain eicosanoid levels during temporary focal ischemia in rats: a microdialysis study. J Neurosurg. Anesthesiol. (1993) 5:41-47.
40. GARCIA J, YOSHIDA Y, CHEN H et al.: Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am. J. Pathol. (1993) 142:623-635.
41. TEISMANN P, TIEU K, CHOI DK et al.: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. PNAS (2003) 100:5473-5478
42. KUNZ T, OLIW EH: The selective cyclooxygenase-2 inhibitor rofecoxib reduces keinate-induced cell death in the rat hippocampus. Eur. J. Neurosci. (2001) 13:569-575.
43. AISEN PS, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA (2003) 289:2819-2826.
44. McGEER PL: Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17:1-11.
45. LAUNER LJ: Non-steroidal anti-inflammatory drugs and Alzheimer's disease: what next? JAMA (2003) 289:2865-2867.
46. HILKENS CM, SNIJDERS A, SNIJDEWINT FG et al.: Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur. Respir. J. (1996) 22(Suppl.):90s-94s.
47. HINSON RM, WILLIAMS JA, SHACTER E: Elevated interleukin 6 is induced by prostaglandin e2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA (1996) 93-4885-4890.
48. STOLINA M, SHARMA S, LIN Y et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. (2000) 164:361-370.
49. HARRIS SG, PADILLA J, KOUMAS L et al.: Prostaglandins as modulators of immunity. Trends Immunol, (2002) 23:144-150.
50. COTTER D, TAKEI N, FARRELL M et al.: Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Schizophr. Res. (1995) 16:233-241.
51. IMPAGNATIELLO F, GUIDOTTI AR, PESOLD, C et al.: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. USA (1998) 95:15718-15723.
52. KOSUGI I, SHINMURA Y, KAWASAKI H et al.: Cytomegalovirus infection of the central nervous system stem cells from mouse embryo: a model for developmental brain disorders induced by cytomegalovirus. Lab. Invest. (2000) 80:1373-1383.
53. RUBIN SA, PLETNIKOV M, CARBONE KM: Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain. J. Virol. (1998) 72:8037-8042.
54. RAMIREZ JC, FAIREN A, ALMENDRAL JM: Parvovirus minute virus of mice strain i multiplication and pathogenesis in the newborn mouse brain are restricted to proliferative areas and to migratory cerebellar young neurons. J. Virol. (1996) 70:8109-8116.
55. LYCKE E, ROOS BE: Virus infections in infant mice causing persistent impairment of turnover of brain catecholamines. J. Neurol. Sci. (1975) 26:49-60.
56. ZALCMAN S, GREEN-JOHNSON JM, MURRAY L et al.: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. (1994) 643:40-49.
57. DANTZER R: Cytokine-induced sickness behavior: Where do we stand? Brain Behav. Immun. (2001) 15:7-24.
58. DANTZER R, BLUTHE R, CASTANON N et al.: Cytokine effects on behavior. In: Psychoneuroimmunology (3rd Edition Volume 2). R Ader, DL Felten, N Cohen (Eds), Academic Press, San Diego, USA (2001):373-382.
59. BAKHIET M, TJERNLUND A, MOUSA A et al.: RANTES promotes growth and survival of human first-trimester forebrain aastrocytes. Nat. Cell. Biol. (2001) 3:150-157.
60. GADIENT RA, OTTEN UH: Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog. Neurobiol. (1997) 52:379-390.
61. KREUTZBERG GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. (1996) 19:312-318.
62. + T cell cytokine profile in experimental allergic encephalomyelitis. Eur. J. Immunol. (1997) 27:2840-2847.
63. ALOISI F, RIA F, ADORINI L: Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol. Today (2000) 21:141-147.
64. MÜLLER N, ACKENHEIL M: Psychoneuroimmunology and the cytokine-network in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiat. (1998) 22:1-33.
65. YOLKEN RH, TORREY EF: Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol, Rev. (1995) 8:131-145.
66. VILLEMAIN F, CHATENOUD L, GALINOWSKI A et al.: Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry (1989) 146:609-616.
67. GANGULI R, BRAR JS, CHENGAPPA KR et al: Mitogen-stimulated interleukin 2 production in never-medicated, first episode schizophrenics - the influence of age of onset and negative symptoms. Arch. Gen. Psychiatry (1995) 52:878.
68. HORNBERG M, AROLT V, WILKE I et al.: Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophrenia Res. (1995) 15:237-242.
69. BESSLER H, LEVENTAL Z, KARP L et al.: Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry (1995) 38:297-302.
70. CAZZULLO CL, SCARONE S, GRASSI B et al.: Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog. Neuro-Psychopharmacol. Biol. Pychiatry (1998) 22:947-957.
71. ROTHERMUND M, AROLT V, WEITZSCH CH et al.: Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry (1998) 22:1294-1297.
72. WILKE I, AROLT V, ROTHERMUNDT M et al.: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. (1996) 246:279-284.
73. RIEDEL M, STRASSNIG M, SPELLMANN I, SIKORSKI CH, MÖLLER HJ, MÜLLER N: Decreased cutaneous immune response in schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. (submitted).
74. SCHWARZ MJ, RIEDEL M, ACKENHEIL M, MÜLLER N: Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry (2000) 47:29-33.
75. GANGULI R, YANG Z, SHURIN G et al.: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. (1994) 51:1-10.
76. MAES M, BOSMANS E, CALABRESE J et al.: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood-stabilizers. J. Pychiatr. Res. (1995) 29:141-152.
77. FROMMBERGER UH, BAUER J, HASELBAUER P et al.: (1997) Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 247:228-233.
78. LIN A, KENIS G, BIGNOTII S et al.: The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Res. (1998) 32:9-15.
79. VAN KAMMEN DP, McALLISTER-SISTILLI CG, KELLEY ME: Relationship between immune and behavioral measures in schizophrenia. In: Current Update in Psychoimmunology G Wieselmann (Ed.), Springer Verlag Wien, NY, USA (1997):51-55.
80. MITTLEMAN BB, CASTELLANOS FX, JACOBSON LK et al.: Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol (1997) 159:2994-2999.
81. SCHWARZ MJ, CHIANG S, MÜLLER N et al.: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. (2001) 15:340-370.
82. MÜLLER N, ULMSCHNEIDER M, SCHEPPACH C et al.: COX-2 inhibition as treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci. (2004) 254:14-22.
83. POLLMÄCHER T. HAACK M, SCHULD A et al.: Effects of antipsychotic drugs to cytokine networks. J. Psychiat. Res. (2000) 34:369-382.
84. MÜLLER N, EMPEL M, RIEDEL M et al.: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. (1997) 247:308-313.
85. MÜLLER N, HADJAMU M, RIEDEL M et al.: The adhesion-molecule receptor expression on T helper cells increases during treatment with neuroleptics and is related to the blood-brain barrier permeability in schizophrenia. Am. J. Psychiatry (1999) 156:634-636.
86. SCHWARZ MJ, ACKENHEIL M, RIEDEL M et al.: Blood-CSF-barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Letters (1998) 253:201-203.
87. SCHWARZ MJ, RIEDEL M, GRUBER R et al.: Levels of soluble adhesion molecules in schizophrenia: Relation to psychopathology. In: Psychiatry, Pychoneureimmunology and Viruses. N Müller (Ed.), Springer Verlag Wien, NY, USA (1999):121-130.
88. MÜLLER N, RIEDEL M, SCHEPPACH C et al.: Beneficial anti-psychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J Pychiatry (2002) 159:1029-1034.
89. MÜLLER N, DOBMEIER P, EMPEL M et al.: Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Eur. Psychiatry (1997) 12:294-299.
90. 2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J. Virol. (2000) 74:5740-5745.
91. BISHOP-BAILEY D, BURKE-GAFFNEY A, HELLEWELL PG et al.: Cyclooxygenase-2 regulates inducable ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1998) 249:44-47.
92. MÜLLER N, RIEDEL M, SCHWARZ MJ et al.: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci (In press).
93. MÜLLER N, ACKENHELL M: Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: The relationship to negative symptomatology. Schizophrenia Res. (1995) 14:223-228.
94. DICKERSON FB, BORONOW JJ, STALLINGS C et al.: Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry (2003) 60:466-472.
95. TEUNISSEN CE, VAN BOXTEL MP, BOSMA H et al.: Inflammation markets in relation to cognition in a healthy aging population. J Neuroimmunol. (2003) 134:142-150.
96. SCALI C, GIOVANNINI MG, PROSPERI C et al.: The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience (2003) 117:909-919.
97. GIOVANNINI MG, SCALI C, PROSPERI C et al.: β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. (2002) 11:257-274.
98. ANDREASSON KI, SAVONENKO A, VIDENSKY S et al.: Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J. Neurosci. (2001) 21:8198-8209.
99. YERMAKOVA A, O'BANION MK: Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders. Curr. Pharmaceutical Design (2000) 6:1755-1776.
100. BAIK EJ, KIM EJ, LEE SH et al.: Cyclooxygenase-2 seletive inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. (1999) 843:118-129.
101. NOGAWA S, ZHANG F, ROSS ME et al.: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. (1997) 17:2746-2755.
102. VAN WEST D, MAES M: Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinol. Lett. (1999) 20:11-17.
103. MÜLLER N, SCHWARZ J: Immunology in anxiety and depression. In: Handbook of depression and anxiety (2nd Edition). S Kasper, JA den Boer, JMA Sitsen (Eds), Marcel Dekker, NY USA(2002) 267-288.
104. DUNBAR PR, HILL J, NEALE TJ et al.: Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychol. Med. (1992) 22:1051-1057.
105. MAES M, SCHARPE S, MELTZER HY et al.: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. (1994) 54:143-160.
106. MAES M, SCHARPE S, MELTZER HY et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. (1993) 49:11-27.
107. MAES M, MELTZER HY, BOSMANS E et al.: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. (1995) 34:301-309.
108. MAES M, BOSMANS E, DE JONGH R et al.: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 9:853-858.
109. SLUZEWSKA A, RYBAKOWSKI J, BOSMANS E et al.: Indicators of immune activation in major depression. Psychiatry Res. (1996) 64:161-167.
110. SONG C, LIN A, BONACCORSO S et al.: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. (1998) 49:211-219.
111. BERK M, WADEE AA, KUSCHKE RH et al.: Acute phase proteins in major depression. J. Pychosom. Res. (1997) 43:529-534.
112. CALABRESE JR, SKWERER AG, BARANA B et al.: (1986) Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 17:41-47.
113. LINNOILA M, WHORTON R, RUBINOW DR et al.: CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry (1983) 40:405-406.
114. NISHINO S, UENO R, OHISHI K et al.: Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry (1989) 146:365-368.
115. SONG C, LEONARD B: Fundamentals of psychoneuroimmunology. J Wiley and Sons (Eds), Chichester, NY, USA (2000).
116. OHISHI K, UENO R, NISHINO S et al.: Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry (1988) 23:326-334.
117. CAO C, MATSUMURA K, OZAKI M et al: Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J. Neurosci. (1999) 19:716-725.
118. COLLANTES-ESTEVES E, FERNANDEZ-PERREZ CH: Improved self-control of osthcoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in spain. Curr. Med Res. Opin. (2003) 19:402-410.
119. SANDRINI M, VITALE G, PINI LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res. (2002) 51:154-159.